Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
BVS(NASDAQ:BVS) DURHAM, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2025, at 1:05 p.m. ET.
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference
BVSDURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Tuesday, August 12, 2025, at 2:00 p.m. ET.
Bioventus Affirms FY2025 Adj EPS Guidance of $0.64-$0.68 vs $0.66 Est; Affirms FY2025 Sales Guidance of $560.00M-$570.00M vs $564.87M Est
BVSBioventus Q1 Adj. EPS $0.08 Beats $0.02 Estimate, Sales $123.88M Beat $122.70M Estimate
BVSExamining the Future: Bioventus's Earnings Outlook
BVSCanaccord Genuity Maintains Buy on Bioventus, Maintains $15 Price Target
BVSMedical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million
BVSBioventus posted strong Q4 results, with EPS and revenue surpassing estimates. The company projects 2025 sales of $560M–$570M and adjusted EPS of $0.64–$0.68.
Korn Ferry Posts Better-Than-Expected Earnings, Joins Bioventus, Endeavour Silver, Vail Resorts And Other Big Stocks Moving Higher On Tuesday
BVSBioventus Expects 2025 Sales Of $560M-$570M Versus Consensus Of $554.62M, With Adjusted EPS Of $0.64 to $0.68 Versus Consensus Of $0.55
BVSBioventus Q4 2024 Adj EPS $0.15 Beats $0.08 Estimate, Sales $153.64M Beat $145.17M Estimate
BVSCanaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $15
BVSBioventus Raises FY24 Adj EPS Guidance from $0.36-$0.42 to $0.40-$0.42 vs $0.39 Est; Sales Guidance from $557M-$567M to $562M-$567M vs $561.77M Est
BVSBioventus Q3 2024 Adj. EPS $0.06 Beats $0.03 Estimate, Sales $138.964M Beat $133.233M Estimate
BVSBioventus Agrees To Nationwide Contract With Cigna Commercial Plans For DUROLANE And GELSYN-3 For Knee Osteoarthritis; No Terms Disclosed
BVS